BC Innovations | Jul 25, 2019
Translation in Brief

Neoantigens in pediatric ALL could lead to cell-based therapies

Despite low tumor mutation load, strong immune responses against predicted neoantigens suggest opportunities to develop immunotherapies for pediatric acute lymphoblastic leukemia. The oncology field is increasingly turning to neoantigens -- non-self antigens arising from mutations...
BC Innovations | Apr 30, 2019
Distillery Therapeutics

RUNX1, RUNX3, CBFB and PMP22 as targets for neurofibromatosis

DISEASE CATEGORY: Cancer INDICATION: Neurofibromatosis Cell culture and mouse studies suggest promoting PMP22 expression, dual RUNX1/RUNX3 inhibition, or inhibiting the interactions of CBFB with RUNX1 and RUNX3 could help treat neurofibromatosis. In mouse neurofibroma Schwann...
BC Innovations | Feb 19, 2009
Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/ marker/pathway Summary Licensing status Publication and contact information Cancer Leukemia Runt-related transcription factor 1 (RUNX1; AML1); runt-related transcription factor 1 translocated to 1 (cyclin D-related) (RUNX1T1; ETO) Studies in...
Items per page:
1 - 3 of 3